In a significant advancement in cancer treatment, Thermo Fisher Scientific Inc. (NYSE: TMO) has partnered with the National Cancer Institute (NCI), a component of the National Institutes of Health, to launch the myeloMATCH precision medicine umbrella trial. This initiative aims to revolutionize the treatment landscape for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) through […]
Thermo Fisher Scientific, a global leader in serving science, has unveiled its latest advancement in bioservices—a state-of-the-art ultra-cold facility located in Bleiswijk, Netherlands. This new facility is designed to bolster the clinical trial network within Europe and enhance the development of cutting-edge therapies. At the forefront of its capabilities, the Bleiswijk facility specializes in the […]
In a significant advancement for the pharmaceutical and biotechnology industry, Thermo Fisher Scientific, a global leader in scientific services, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Agency (AIFA). This certification allows the company’s Monza, Italy facility to manufacture RNA-based products, marking a pivotal moment for Thermo Fisher Scientific and the broader […]
Verici Dx plc, a pioneer in clinical diagnostics for organ transplant, has announced an exclusive global licensing agreement with Thermo Fisher Scientific, a world leader in science services, to develop a diagnostic assay for early kidney rejection risk assessment. Exclusive Licensing Terms The agreement provides Thermo Fisher with exclusive rights to develop and market the […]
Fisher Scientific, a global leader in serving science, unveiled its latest product, the Gibco OncoPro Tumoroid Culture Medium Kit to expedite development of novel cancer therapies. This product is distinguished as the first commercially available culture medium explicitly crafted for the expansion of patient-derived tumoroids, also known as cancer organoids, from various cancer indications. The […]
Thermo Fisher Scientific has inaugurated a sterile drug facility in Singapore, in a move to enhance the ability of its customers to deliver novel medicines and vaccines in the Asia-Pacific market. This sterile drug plant not only represents a significant milestone but also underscores Singapore’s dedication to pandemic readiness and its emergence as a prominent […]
Thermo Fisher Scientific, an American analytical laboratory instrument manufacturing company, has closed the previously announced acquisition of The Binding Site Group, a UK- based diagnostic products manufacturer, for £2.3 billion ($2.8 billion) in cash. The acquisition complements and adds to Thermo Fisher Scientific’s existing specialty diagnostics offering in oncology. The Binding Site offers specialty diagnostic […]
Thermo Fisher Scientific has agreed to acquire The Binding Site Group, a UK-based specialist protein diagnostics company, for £2.25 billion ($2.6 billion) in an all-cash deal from a shareholder consortium led by Nordic Capital. The Binding Site Group offers specialty diagnostic assays and instruments to help in the diagnosis and management of immune system disorders […]
Moderna has entered into a 15-year collaboration agreement with Thermo Fisher Scientific to enable dedicated large-scale US manufacturing of Spikevax, the former’s Covid-19 vaccine as well as other investigational messenger RNA (mRNA) medicines in its pipeline. The agreement is said to make use of exclusive commercial fill-finish manufacturing capacity in the US for mRNA vaccines […]
Thermo Fisher Scientific has agreed to acquire PPD, a US-based clinical research services provider, for $47.50 per share or $20.9 billion. The consideration includes assumption of nearly $3.5 billion of the contract research organization’s net debt. Based in North Carolina, PPD caters to the pharma and biotech industry with a variety of clinical research and […]